William P. Donnelly Buys 93,113 Shares of Quanterix Co. (NASDAQ:QTRX) Stock

Quanterix Co. (NASDAQ:QTRX - Get Free Report) Director William P. Donnelly bought 93,113 shares of the company's stock in a transaction that occurred on Friday, June 6th. The stock was bought at an average price of $5.44 per share, with a total value of $506,534.72. Following the acquisition, the director now directly owns 139,094 shares in the company, valued at $756,671.36. The trade was a 202.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Quanterix Stock Down 7.1%

Quanterix stock traded down $0.47 during trading on Thursday, reaching $6.19. The stock had a trading volume of 730,843 shares, compared to its average volume of 591,636. Quanterix Co. has a 52-week low of $4.05 and a 52-week high of $19.18. The business has a 50 day moving average price of $5.30 and a 200 day moving average price of $7.85. The stock has a market cap of $240.35 million, a PE ratio of -5.84 and a beta of 1.05.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.16. The business had revenue of $30.33 million during the quarter, compared to analysts' expectations of $28.27 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. On average, equities analysts predict that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Institutional Trading of Quanterix

A number of institutional investors have recently bought and sold shares of the business. Ameriprise Financial Inc. raised its position in shares of Quanterix by 111.3% during the 4th quarter. Ameriprise Financial Inc. now owns 3,205,928 shares of the company's stock worth $34,079,000 after acquiring an additional 1,688,680 shares in the last quarter. Portolan Capital Management LLC increased its stake in Quanterix by 2.7% in the fourth quarter. Portolan Capital Management LLC now owns 2,587,824 shares of the company's stock valued at $27,509,000 after purchasing an additional 67,138 shares during the last quarter. Vanguard Group Inc. raised its holdings in Quanterix by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,217,225 shares of the company's stock worth $23,569,000 after purchasing an additional 19,386 shares in the last quarter. Millennium Management LLC raised its holdings in Quanterix by 6.0% during the fourth quarter. Millennium Management LLC now owns 2,185,101 shares of the company's stock worth $23,228,000 after purchasing an additional 122,969 shares in the last quarter. Finally, Easterly Investment Partners LLC lifted its position in shares of Quanterix by 38.8% during the 1st quarter. Easterly Investment Partners LLC now owns 1,325,620 shares of the company's stock worth $8,630,000 after buying an additional 370,625 shares during the last quarter. 86.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on QTRX. Leerink Partnrs cut shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Canaccord Genuity Group cut their target price on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Leerink Partners reissued a "market perform" rating and issued a $8.00 price target (down previously from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Quanterix has an average rating of "Hold" and a consensus price target of $15.60.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.